ZA202209623B - A pharmaceutical composition and method of treatment using serratiopeptidase, mannose or its derivative, and optionally antinfection agents - Google Patents

A pharmaceutical composition and method of treatment using serratiopeptidase, mannose or its derivative, and optionally antinfection agents

Info

Publication number
ZA202209623B
ZA202209623B ZA2022/09623A ZA202209623A ZA202209623B ZA 202209623 B ZA202209623 B ZA 202209623B ZA 2022/09623 A ZA2022/09623 A ZA 2022/09623A ZA 202209623 A ZA202209623 A ZA 202209623A ZA 202209623 B ZA202209623 B ZA 202209623B
Authority
ZA
South Africa
Prior art keywords
serratiopeptidase
mannose
pharmaceutical composition
agents
antinfection
Prior art date
Application number
ZA2022/09623A
Other languages
English (en)
Inventor
Patel Nimesh
Original Assignee
Patel Nimesh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patel Nimesh filed Critical Patel Nimesh
Publication of ZA202209623B publication Critical patent/ZA202209623B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/2404—Serralysin (3.4.24.40)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2022/09623A 2020-03-02 2022-08-29 A pharmaceutical composition and method of treatment using serratiopeptidase, mannose or its derivative, and optionally antinfection agents ZA202209623B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062984135P 2020-03-02 2020-03-02
PCT/US2021/020411 WO2021178371A1 (en) 2020-03-02 2021-03-02 A pharmaceutical composition and method of treatment using serratiopeptidase, mannose or its derivative, and optionally antinfection agents

Publications (1)

Publication Number Publication Date
ZA202209623B true ZA202209623B (en) 2023-12-20

Family

ID=77463237

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/09623A ZA202209623B (en) 2020-03-02 2022-08-29 A pharmaceutical composition and method of treatment using serratiopeptidase, mannose or its derivative, and optionally antinfection agents

Country Status (9)

Country Link
US (1) US20210268075A1 (https=)
EP (1) EP4114407A4 (https=)
JP (1) JP7758906B2 (https=)
CN (1) CN115361953A (https=)
AU (1) AU2021229482A1 (https=)
BR (1) BR112022016132A2 (https=)
CA (1) CA3164767A1 (https=)
WO (1) WO2021178371A1 (https=)
ZA (1) ZA202209623B (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007099639A (ja) * 2005-09-30 2007-04-19 Towa Chem Ind Co Ltd 除菌洗浄剤
WO2008035370A2 (en) * 2006-07-10 2008-03-27 Advanced Enzyme Technologies Limited Compositions for prevention and treatment of mastitis and metritis
EP2690105A1 (en) * 2012-07-24 2014-01-29 Centre National De La Recherche Scientifique Mannose derivatives, a process for preparing the same and their uses as a drug
ITMI20130793A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
CN105682665A (zh) * 2013-05-30 2016-06-15 华盛顿大学 用于治疗细菌性感染的化合物和方法
US20190000908A1 (en) * 2017-06-29 2019-01-03 Hms Laboratories Ltd. Compositions and methods for treating and/or preventing a urinary tract infection
US11707065B2 (en) * 2017-07-18 2023-07-25 Mc (Us) 3 Llc Method for biofilm dispersal
CN116115768B (zh) * 2022-12-01 2025-03-18 西南民族大学 一种抗菌剂及其制备方法和应用

Also Published As

Publication number Publication date
US20210268075A1 (en) 2021-09-02
BR112022016132A2 (pt) 2023-01-10
EP4114407A1 (en) 2023-01-11
AU2021229482A1 (en) 2022-07-28
WO2021178371A1 (en) 2021-09-10
CN115361953A (zh) 2022-11-18
CA3164767A1 (en) 2021-09-10
JP2023515880A (ja) 2023-04-14
JP7758906B2 (ja) 2025-10-23
EP4114407A4 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
ZA202403388B (en) Small molecules for treatement of cancer
NO20080338L (no) Forbindelser for behandling av multilegemiddelresistente bakterielle infeksjoner
MX391655B (es) Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo
NO20076675L (no) Aminopiperidinquinoliner og deres azaisosteriske analoger med antibakteriell aktivitet
BR9507099A (pt) Forma de dosagem método de esterilização composição esterilizante e suplemento alimentar animal compreendendo nitrito acidificado como um agente anti-microbiano
ZA202300259B (en) Compound for the treatment of coronaviral infections
IL284930A (en) History of pyrrolopyrimidines and their use in the treatment of protein kinase-related diseases
NO20062703L (no) Maleatsalter av et kinazolinederivater anvenbare som antiangiogenisk middel
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
MX2023008923A (es) Composicion farmaceutica que comprende un derivado de difenilpirazina.
SG11201908234WA (en) Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
MX2022011203A (es) Compuestos de 9-aminometil minociclina y usos de los mismos.
UA112418C2 (uk) Терапевтичний болезаспокійливий засіб
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
BR112022009881A2 (pt) Inibidores de caspase 6 e usos dos mesmos
CL2025003690A1 (es) Compuestos anti-vih.
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
ZA202209623B (en) A pharmaceutical composition and method of treatment using serratiopeptidase, mannose or its derivative, and optionally antinfection agents
ZA202211004B (en) 3clpro-targeting phillyrin, derivative thereof, and use thereof against novel coronavirus
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.
BR112023026356A2 (pt) Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
MX2022011596A (es) Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae.
BR112022003639A2 (pt) Agente bioestimulante para tratamento de plantas e/ou de sementes de plantas